Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant

E. Nikolousis, S. Robinson, S. Nagra, C. Brookes, F. Kinsella, S. Tauro, S. Jeffries, M. Griffiths, P. Mahendra, M. Cook, S. Paneesha, R. Lovell, B. Kishore, S. Chaganti, R. Malladi, M. Raghavan, P. Moss, D. Milligan, C. Craddock

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    In this multicentre retrospective study we have studied the impact of T cell chimerism on the outcome of 133 patients undergoing an alemtuzumab based reduced intensity conditioning allograft (RIC). The median age of the patients was 50 years (range 42-55 years). 77 patients were transplanted using an HLA identical sibling donor while 56 patients received a fully matched volunteer unrelated donor graft. 64 patients had a lymphoid malignancy and 69 were transplanted for a myeloid malignancy. 38 patients (29%) relapsed with no significant difference in risk of relapse between patients developing full donor and mixed donor chimerism in the T-cell compartment on D + 90 and D + 180 post transplant. Day 90 full donor T cell chimerism correlated with an increased incidence of acute GVHD according to NIH criteria (p = 0.0004) and the subsequent development of chronic GVHD. Consistent with previous observations, our results confirmed a correlation between the establishment of T cell full donor chimerism and acute GVHD in T deplete RIC allografts. However our study failed to identify any correlation between T cell chimerism and relapse risk and challenge the use of pre-emptive donor lymphocyte infusions (DLI) in patients with mixed T cell chimerism transplanted using an alemtuzumab based RIC regimen. (C) 2013 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)561-565
    Number of pages5
    JournalLeukemia Research
    Volume37
    Issue number5
    DOIs
    Publication statusPublished - May 2013

    Keywords

    • KINETICS
    • MINIMAL RESIDUAL DISEASE
    • SURVIVAL
    • PATTERNS
    • T cell chimerism
    • IN-VIVO
    • ENGRAFTMENT
    • Reduced intensity transplant
    • Alemtuzumab
    • MIXED CHIMERISM
    • BONE-MARROW-TRANSPLANTATION
    • TOXICITY
    • HEMATOLOGIC MALIGNANCIES

    Cite this

    Nikolousis, E., Robinson, S., Nagra, S., Brookes, C., Kinsella, F., Tauro, S., Jeffries, S., Griffiths, M., Mahendra, P., Cook, M., Paneesha, S., Lovell, R., Kishore, B., Chaganti, S., Malladi, R., Raghavan, M., Moss, P., Milligan, D., & Craddock, C. (2013). Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. Leukemia Research, 37(5), 561-565. https://doi.org/10.1016/j.leukres.2013.01.010